Rasagiline Mesylate

甲磺酸雷沙吉兰

Report date: 2026/05/13 20:02:10
NME

Base Information

Drug NameRasagiline Mesylate
Drug Alias Name雷萨吉兰甲磺酸盐Rasagilinumrasagilina雷沙吉兰甲烷磺酸盐吉兰甲磺酸盐 +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMonoamine oxidase B inhibitors
TargetsMonoamine oxidase B
Therapy Area/IndicationsREM Sleep Behavior DisorderRestless Legs SyndromeSynucleinopathies +[8] 
Global Approved IndicationsParkinson Disease
Approved Indications in ChinaParkinson Disease
Original Approved Country/TerritoryEU
Original Approved Date2005/02/21
Country/TerritoryCanadaUnited StatesPortugal +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTeva
China Registration ClassN/A

Develop Information

Active CompaniesTeva BvTakeda Pharmaceutical Co LtdTeva Pharmaceutical Industries Ltd
Inactive CompaniesUniversity Of FloridaTeva Neuroscience IncTeva Branded Pharmaceutical Products R&D Inc +[10] 
Active IndicationsParkinson Disease
Inactive IndicationsREM Sleep Behavior DisorderRestless Legs SyndromeSynucleinopathies +[7] 

Other Information

ATC CodeN04BD02
Related LinksWikipediaDrugBankKEGG